Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial RNA Pseudouridylation-Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RPUSD4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RPUSD4 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic assays and biophysical binding studies. |
View RPUSD4 Products |
| Gene Delivery | RPUSD4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for functional validation of mitochondrial translation and OXPHOS. |
View RPUSD4 Products |
| Benchmark Ab | Anti-RPUSD4 Recombinant Antibody Recombinant positive control for western blot, IP, and immunofluorescence validation. |
View RPUSD4 Products |
| Validator | RPUSD4 siRNA Set For knockdown verification to confirm phenotype reversal in cancer cell lines. |
View RPUSD4 Products |
| Related Target A | PUS1 RNA pseudouridylate synthase 1. Crucial for selectivity counter-screening to avoid off-target toxicity. |
View PUS1 Products |
| Related Target B | PUS7 Another key pseudouridine synthase. Required for profiling the specificity of small-molecule inhibitors. |
View PUS7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial Localization & Folding | Recombinant RPUSD4 proteins designed with precise transit peptide truncation to ensure soluble, correctly folded active domains. |
| Selectivity Screening Against PUS Homologs | Comprehensive panel of PUS family proteins (PUS1, PUS7, DKC1) available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Sequence-verified benchmark antibodies and positive control expression plasmids included. |
| False Positives in Phenotypic Assays | Validated siRNA sets included to confirm that small-molecule phenotypes match genetic knockdown. |
Live RPUSD4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RPUSD4 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum mitochondrial inhibitors to targeted epitranscriptomic modulators. As first-generation therapies targeting mitochondrial translation reach preclinical milestones, the next wave of R&&D is targeting the specific inhibition of RPUSD4-mediated pseudouridylation of mitochondrial 16S rRNA and tRNAs to selectively disrupt cancer cell metabolism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Breast Cancer, Colorectal Cancer, Osteosarcoma | Enzymatic Assay (Need high-purity, active recombinant RPUSD4 protein) |
| RNA Interference (siRNA/shRNA) | RNAi Therapeutics Developers | Refractory Solid Tumors | In vitro knockdown verification (Need validated siRNA sets) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Companies | Metastatic Cancers, OXPHOS-dependent tumors | Selectivity & Degradation Assay (Need stable cell lines via Lentivirus) |